Hematology 2nd Special Issue 2020

In this special hematology focused issue of CURE® we look at all the promising treatments and research for both adults and children with blood cancers.

Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).

Finding the best care team can make all the difference for patients with diseases like multiple myeloma.

Clinical trials lead to new cancer treatments — and can give a patient access to effective drugs years before they’re made available to the public.

For years, childhood blood cancers were understudied forcing patients’ treatments into a one size-fits-all approach. But new efforts are changing that.

Weighing the cost of CAR-T cell therapy in treating blood cancers is a finical burden for many patients with blood cancer.

Exciting advances in treatment options for patients with mantle cell lymphoma are greatly improving the outlook for long-term remissions.

CAR-T Cell therapy is expanding in the field of blood cancers, but it comes with a host of side effects patients need to look out for. One study is looking to get ahead of the side effect curve for patients about to undergo CAR-T cell therapy.